Tidal Investments’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-6,302
Closed -$207K 1663
2023
Q4
$207K Sell
6,302
-1,722
-21% -$46.8K ﹤0.01% 1335
2023
Q3
$224K Sell
8,024
-666
-8% -$21.8K 0.01% 1175
2023
Q2
$296K Sell
8,690
-881
-9% -$27.7K 0.01% 1052
2023
Q1
$288K Buy
9,571
+308
+3% +$9.54K 0.01% 1018
2022
Q4
$262K Sell
9,263
-152
-2% -$4.82K 0.01% 924
2022
Q3
$309K Sell
9,415
-2,873
-23% -$105K 0.01% 739
2022
Q2
$387K Buy
12,288
+866
+8% +$30.3K 0.01% 686
2022
Q1
$525K Buy
11,422
+2,289
+25% +$109K 0.02% 636
2021
Q4
$559K Buy
9,133
+4,868
+114% +$337K 0.02% 567
2021
Q3
$319K Buy
4,265
+71
+2% +$5.96K 0.01% 664
2021
Q2
$388K Buy
4,194
+395
+10% +$33.6K 0.02% 496
2021
Q1
$337K Sell
3,799
-388
-9% -$38.5K 0.02% 387
2020
Q4
$390K Sell
4,187
-1,976
-32% -$157K 0.03% 265
2020
Q3
$392K Sell
6,163
-3,723
-38% -$218K 0.05% 176
2020
Q2
$515K Sell
9,886
-4,819
-33% -$207K 0.07% 155
2020
Q1
$459K Buy
+14,705
New +$491K 0.14% 125

Other funds holding ARKG

Tidal Investments's ARKG Position: Q1 2024 in Review

Tidal Investments sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 6,302 shares — an estimated $207K sold.

Tidal Investments first reported a position in ARKG in Q1 2020 and held it in 16 quarters. The position peaked at $559K in Q4 2021. 284 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

  • Tidal Investments reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
  • Tidal Investments sold 6,302 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $207K.
  • Tidal Investments first reported a position in ARK Genomic Revolution ETF in Q1 2020 and held it in 16 quarters.
  • Tidal Investments's ARK Genomic Revolution ETF position peaked at $559K in Q4 2021.
  • 284 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on Tidal Investments's 13F filing for Q1 2024, filed 16 May 2024.